Effects of pharmacological myocardial depression on coronary artery collateral formation

Surgery
|June 1, 1975
PubMed

Insights

Beta-blocker treatment for angina may hinder the development of new blood vessels (collateralization) in the heart. This experimental study in dogs suggests reduced collateral formation when oxygen demand is pharmacologically lowered.

Area of Science:

  • Cardiology
  • Pharmacology
  • Experimental Medicine

Background:

  • Angina pectoris treatment involves increasing blood flow or reducing oxygen demand.
  • Beta-blockers reduce myocardial oxygen demand but may impede collateralization.
  • The impact of beta-blockade on coronary collateral development requires investigation.

Purpose of the Study:

  • To investigate the effect of propranolol (a beta-blocker) on experimentally induced coronary collateralization.
  • To determine if reducing myocardial oxygen demand interferes with the formation of new blood vessels in the heart.

Main Methods:

  • 25 dogs underwent ameroid constrictor placement to induce collateralization.
  • Groups received immediate propranolol, delayed propranolol, or no propranolol treatment.
  • Evaluations included surface mapping, angiographic collateral mapping, and hemodynamic studies.

Main Results:

  • Acute propranolol treatment significantly depressed collateral formation.
  • Hemodynamic evidence showed reduced coronary flow and altered pressures in treated dogs.
  • Effects on established collaterals with delayed treatment were inconsistent.

Conclusions:

  • Pharmacological reduction of myocardial oxygen demand experimentally reduces coronary collateralization.
  • Beta-blocker use in multivessel coronary disease warrants further evaluation, especially compared to direct bypass.
  • Findings suggest potential limitations of beta-blockers in promoting compensatory blood flow in certain coronary conditions.

Related Concept Videos

Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...